Companies: 10,795·Total market cap: $144.5T
Telix Pharmaceuticals Limited

Telix Pharmaceuticals Limited

TLXNASDAQHealthcare● Active
$9.27
$-0.03(-0.32%)
Market Cap$3.1B
P/E Ratio—
52W High$18.49
52W Low$6.28
Overview
Foreign Private Issuer · Files 20-F / 6-K

Telix Pharmaceuticals Limited (TLX) SEC Filings & 10-K Annual Reports

SEC EDGAR regulatory submissions (10-K, 10-Q, 8-K), latest forms, and full filing history — quick links to financials and earnings below.

SEC EDGAR · data.sec.gov · CIK 0002007191 · TLX · NASDAQ · as of Jun 8, 2026

Filing snapshot

95
Total Filings
6-K
Latest Form
2026-05-21
Most Recent
2024
Filing Since
FinancialsEarningsView All on EDGAR

Source: SEC EDGAR (data.sec.gov) · CIK 0002007191 · Updated hourly · Not investment advice

Latest Annual Report

20-F · Annual Report (Foreign Issuer)FY
Filed Date
2026-02-20
Fiscal Year End
Feb 20, 2026
Accession No.
0001628280-26-009943
Primary Document
tlx-20251231.htm
View on SEC EDGARDownload PDFFiling Index
Source: data.sec.gov · CIK 0002007191 · Accession 0001628280-26-009943

Latest Key Filings

6-KQuarterly Report
CURRENT REPORT OF FOREIGN ISSUER PURSUANT TO RULES 13A-16 AND 15D-16 AMENDMENTS
2026-05-21
View 6-K on SEC
8-KCurrent Report

No recent filings

Form 4Insider Activity
Ownership Change Disclosures

Executive & director trade disclosures. Full buy/sell sentiment analysis on the dedicated tab.

View Insider Trades Tab

SEC Filing History

Hide Form 4 / 144
6-KCurrent Report (Foreign Issuer)
CURRENT REPORT OF FOREIGN ISSUER PURSUANT TO RULES 13A-16 AND 15D-16 AMENDMENTS
2026-05-21
View
3Initial Statement of Beneficial Ownership
FORM 3
2026-05-18
View
3Initial Statement of Beneficial Ownership
FORM 3
2026-05-18
View
3Initial Statement of Beneficial Ownership
FORM 3
2026-05-18
View
6-KCurrent Report (Foreign Issuer)
CURRENT REPORT OF FOREIGN ISSUER PURSUANT TO RULES 13A-16 AND 15D-16 AMENDMENTS
2026-04-23
View
6-KCurrent Report (Foreign Issuer)
CURRENT REPORT OF FOREIGN ISSUER PURSUANT TO RULES 13A-16 AND 15D-16 AMENDMENTS
2026-04-21
View
6-KCurrent Report (Foreign Issuer)
CURRENT REPORT OF FOREIGN ISSUER PURSUANT TO RULES 13A-16 AND 15D-16 AMENDMENTS
2026-04-20
View
6-KCurrent Report (Foreign Issuer)
6-K
2026-04-14
View
6-KCurrent Report (Foreign Issuer)
6-K
2026-04-14
View
6-KCurrent Report (Foreign Issuer)
CURRENT REPORT OF FOREIGN ISSUER PURSUANT TO RULES 13A-16 AND 15D-16 AMENDMENTS
2026-04-13
View
6-KCurrent Report (Foreign Issuer)
6-K
2026-04-10
View
6-KCurrent Report (Foreign Issuer)
6-K
2026-04-09
View
6-KCurrent Report (Foreign Issuer)
6-K
2026-04-07
View
6-KCurrent Report (Foreign Issuer)
CURRENT REPORT OF FOREIGN ISSUER PURSUANT TO RULES 13A-16 AND 15D-16 AMENDMENTS
2026-04-02
View
3Initial Statement of Beneficial Ownership
FORM 3
2026-04-01
View
Showing 1–15 of 93 filingsForm 4 / 144 hidden· 95 total in EDGAR

About SEC Filings & 10-K Annual Reports

Data source: SEC EDGAR (data.sec.gov)  |  Updated: Hourly  |  CIK: 0002007191  |  Exchange: NASDAQ · Healthcare

Telix Pharmaceuticals Limited (NASDAQ: TLX) has submitted 95 documents to the U.S. Securities and Exchange Commission (SEC) since its IPO in 2024. As a Healthcare sector company with CIK 0002007191, all filings are publicly accessible via the EDGAR database at no cost.

The annual 10-K report is Telix Pharmaceuticals Limited's most comprehensive regulatory disclosure. The most recent Telix Pharmaceuticals Limited 10-K was filed on 2026-02-20 for fiscal year ending 2026. Historical TLX 10-K annual reports are available from 2024 through 2026.

Investors researching Telix Pharmaceuticals Limited SEC filings can access 10-K annual reports, quarterly 10-Q reports, material event 8-K filings, and proxy statements directly from the links above. All documents are sourced from the official SEC EDGAR system.

Source: SEC EDGAR · data.sec.gov · SEC Form 10-K · SEC Form 10-Q · SEC Form 8-K2026-06-08
Related Companies SEC Filings — Healthcare
BLTE SEC Filings →PRAX SEC Filings →LGND SEC Filings →MIRM SEC Filings →CELC SEC Filings →ACAD SEC Filings →DYN SEC Filings →SLNO SEC Filings →
→ TLX Financials→ TLX Earnings→ TLX Insider Trades

Frequently Asked Questions

TLX SEC Filings · 8 questions

Telix Pharmaceuticals Limited (TLX) SEC filings are publicly available on this page and on the official SEC EDGAR database at sec.gov. You can browse all 95 filings and access original documents at no cost. Telix Pharmaceuticals Limited's CIK is 0002007191.

TLX SEC filingsTelix Pharmaceuticals Limited SEC documentsfind TLX 10-K